

## 5th CEE Meeting on Viral Hepatitis and HIV

19 - 20 September 2019, Vilnius, Lithuania

version 22.1.19

### Thursday 19 September

<b>8:45</b>	<b>Opening of the Workshop</b>	
<b>Session 1</b>	<b>Epidemiology of HIV and hepatitis in the CEE countries and access to care</b>	
<b>9:00</b>	Epidemiology of viral hepatitis infection and treatment in Europe	Erika Duffel, ECDC
<b>9:30</b>	Epidemiology of HIV infection and treatment in Europe	Teymur Noori, ECDC
<b>10:00</b>	Where we are in terms of providing access and where we should go (based on the WHO Access RoadMap and Plan of Action):	rs Mozalevskis, WHO Europe
<b>10:30</b>	<b>Coffee Break and poster viewing</b>	
<b>Session 2</b>	<b>Access to care</b>	
<b>11:00</b>	EECA: are we lagging behind? (to focus on progress in the region, disparities, similarities etc.)	Sergey Golovin, ITPCru
<b>11:10</b>	Access to quality assured (WHO prequalified) generic medicines in the region	Liudmyla Maistat, Medicines Patent Pool
<b>11:20</b>	Access to key populations (to speak about specific barriers we need to overcome)	Nikos Dedes, EATG
<b>11:30</b>	Roundtable Discussion	ECDC, WHO, ITPCro, MPP, EATG
<b>Session 3</b>	<b>HIV and Hepatitis coinfection</b>	
<b>11:45</b>	Management of HIV/HCV in young women	Vadim Rassokhin , Russia
<b>12:00</b>	Abstract driven presentations - 2 slots	
<b>12:20</b>	Discussion	
<b>12:30</b>	<b>Group picture and Lunch</b>	
<b>13:30</b>	Industry-sponsored symposium - ViiV Case-based presentations Adherence	
<b>Session 3</b>	<b>PrEP</b>	
<b>14:30</b>	Barriers to the PrEP and STI testing in CEE	
<b>14:50</b>	PrEP: what works? What are the remaining challenges?	
<b>15:10</b>	Abstract driven presentation - 2 slots	
<b>15:30</b>	Discussion	
<b>15:35</b>	<b>Coffee Break and poster viewing</b>	
<b>Session 4</b>	<b>Linkage to care and management of treatment failure in HIV</b>	
<b>16:05</b>	Switching to second line HIV therapy	
<b>16:35</b>	Integrated testing for HIV, hepatitis and STIs	Dorthe Raben, Denmark
<b>17:05</b>	Abstract - driven presentations (2 slots)	
<b>17:25</b>	Discussion	
<b>17:30</b>	Industry-sponsored symposium- Abbvie option 1	
<b>18.30</b>	<b>End of Day 1 Program</b> Welcome reception & Poster viewing	
<b>19.00</b>	Workshop Dinner	

## Friday 20 September

**8:30 Industry-sponsored symposium - Abbvie option 2**

**Session 5 HIV and Tuberculosis coinfection**

<b>9:30</b>	Management TB and HIV infection	Daria Podlekareva
<b>10:00</b>	The challenging TB case: clinician and PK expert can solve it together	Jonathan Shapiro, Israel/Liverpool PK Expert
<b>10:30</b>	Abstract driven presentations - 2 slots	
<b>10:50</b>	Discussion	

**11:00 Coffee Break and poster viewing**

**11:30 Industry-sponsored symposium - Gilead**

**12:30 Lunch**

**Session 6 Hot topics in HIV and Hepatitis**

<b>13:30</b>	Vaccinations for HIV patients: which vaccinations when and how?	Carolynne Schwarze -Zander, Germany
<b>13:55</b>	Management of HBV resistance (case-based)	
<b>14:20</b>	HIV/HCV coinfection: what is the impact on risk for cancer and cardiovascular events? How can HCV treatment induced SVR help?	
<b>14:45</b>	Hepatitis E in HIV-infected patients	Sven Pischke, Germany
<b>15:10</b>	<b>End of meeting</b>	